"Ganciclovir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
| Descriptor ID |
D015774
|
| MeSH Number(s) |
D03.633.100.759.758.399.454.250.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ganciclovir".
Below are MeSH descriptors whose meaning is more specific than "Ganciclovir".
This graph shows the total number of publications written about "Ganciclovir" by people in this website by year, and whether "Ganciclovir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1995 | 2 | 1 | 3 |
| 1996 | 2 | 0 | 2 |
| 1997 | 4 | 3 | 7 |
| 1998 | 0 | 1 | 1 |
| 1999 | 2 | 1 | 3 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 1 | 3 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 1 | 3 |
| 2010 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2015 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ganciclovir" by people in Profiles.
-
Congenital Cytomegalovirus and Neonatal Herpes Simplex Virus Infections: To Treat or Not to Treat? Pediatr Infect Dis J. 2019 06; 38(6S Suppl 1):S60-S63.
-
Cytomegalovirus infection in heart transplantation: A single center experience. Transpl Infect Dis. 2018 Aug; 20(4):e12896.
-
Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015 Mar 05; 372(10):933-43.
-
Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients. Transpl Infect Dis. 2014 Dec; 16(6):941-50.
-
Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013 Aug; 14(9):823-33.
-
Hepatitis E virus infection in a liver transplant recipient in the United States: a case report. Transplant Proc. 2013 Mar; 45(2):810-3.
-
The use of antiviral drugs during the neonatal period. Clin Perinatol. 2012 Mar; 39(1):69-81.
-
In vivo imaging of DNA lipid nanocapsules after systemic administration in a melanoma mouse model. Int J Pharm. 2012 Feb 14; 423(1):108-15.
-
Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients. HPB (Oxford). 2010 Dec; 12(10):657-63.
-
Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med. 2010 Jun 15; 152(12):761-9.